Alluvi, previously BI 4744, offers a significant breakthrough in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates remarkable efficacy in https://alluvi-healthcare238102.deliverblog.com/profile